Pharmalittle: Lilly’s Obesity Drug & EU Pharma Rules
- Although quite chilly so far, the clear, blue skies and warm sunshine are a heartening elixir for a busy day ahead.
- Eli lilly's next-generation obesity drug, retatrutide, has demonstrated what appears to be the most ample weight loss observed to date in a late-stage clinical trial.
- In a 68-week Phase 3 study involving patients with obesity and knee osteoarthritis, participants receiving the highest dose of retatrutide and remaining on the drug experienced an average...
“`html
Pharmaceutical News roundup: Retatrutide & EU Drug Regulations
Table of Contents
Top of the morning to you,and a fine one it is. Although quite chilly so far, the clear, blue skies and warm sunshine are a heartening elixir for a busy day ahead. to cope, we are brewing fresh cups of stimulation. Our choice today is chocolate raspberry. As always you are invited to join us. Meanwhile, here are a few items of interest to get you started on your own journey, which we hope will be informative and exciting. Keep in touch, everyone …
Eli Lilly’s Retatrutide: Promising Weight Loss, Significant Side Effects
Eli lilly’s next-generation obesity drug, retatrutide, has demonstrated what appears to be the most ample weight loss observed to date in a late-stage clinical trial. Though,the trial also revealed high rates of side effects,leading to a significant number of participants discontinuing treatment,including some who reported losing too much weight. STAT provides detailed coverage of the findings.
In a 68-week Phase 3 study involving patients with obesity and knee osteoarthritis, participants receiving the highest dose of retatrutide and remaining on the drug experienced an average weight loss of 28.7%. Analyzing all treated participants, including those who discontinued, showed an efficacy of 23.7%. Discontinuation rates due to adverse events ranged from 12% to 18% across the treated cohorts, substantially higher than the 4% observed in the placebo group.Even among patients with the highest body Mass Index (BMI) – those exceeding 35 – discontinuation rates remained elevated, ranging from 9% to 12% compared to 5% in the placebo arm.
Understanding Retatrutide’s Mechanism & Potential
Retatrutide is a triple-GIP and GLP-1 receptor agonist. This means it targets three key hormones involved in appetite regulation and glucose control. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are incretin hormones that enhance insulin secretion and suppress glucagon release. By activating both receptors, retatrutide aims to provide a more potent effect on weight loss and metabolic health than drugs targeting only GLP-1, like semaglutide (Ozempic, Wegovy).
| Treatment Group | Average Weight Loss (%) | Discontinuation Rate (Adverse Events) |
|---|---|---|
| Retatrutide (Highest dose, Completers) | 28.7% | 12-18% |
| Retatrutide (All Treated) | 23.7% | 12-18% |
| Placebo | – | 4% |
EU Pharma Package: Modernizing Medicine Rules
Negotiators from the European Union Council and Parliament have reached a provisional agreement on a “pharma package” designed to modernize pharmaceutical regulations, accelerate patient access to medicines, and strengthen the competitiveness of the European pharmaceutical industry.